The Eli Lilly MDR-TB Partnership: Creating Private and Public Value Case Solution

In 2003, the pharmaceutical manufacturer Eli Lilly MDR-TB created the Alliance in the fight against MDR-TB, a form of tuberculosis. An estimated 450,000 new cases of this disease are reported each year, mainly in China, India and Russia. Partnership, an alliance of 14 public and private organizations, attempted to transfer technology to increase the supply of drugs that could cure MDR-TB, health workers trying to design effective strategies for diagnosis and treatment and publicly promote treatment adequacy of MDR-TB with the support of the community, patient advocacy, and awareness in the workplace. The association has become a successful organization, but the reality of technology transfer across borders of the two organizations and countries was a challenge. It was also difficult for Lilly, a large pharmaceutical company to establish credibility with NGOs whose objective is the treatment of patients with MDR-TB in remote areas of the world. The initial investment of $ 70,000,000 Lilly was insufficient and commitment was increased to 120 million. Where you can discuss topics such as: What is the public value created and how could it be supported by the initiative of Lilly? What are the risks of technology transfer to manufacturing partners pharmaceutical products in various countries? What were the motivations of the partners in this case? What can be the health ministers of each country to make the most effective partnership? What were the benefits and risks for a company the size of Lilly to launch and manage an association of this complexity? Did Lilly lessons that could be applied to other global health problems? Number HKS case 1871.0
Jessica Droste Yagan
28 pages.
Release Date: October 5, 2007. Prod #: HKS239-PDF-ENG
Eli Lilly MDR-TB Partnership: Creation and analysis of private settlement of public value

The Eli Lilly MDR-TB Partnership: Creating Private and Public Value Case Solution
Share This